Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis

Currently, about 50% of patients with metastatic renal cell carcinoma (mRCC) receive a second-line therapy. Therefore, the choice at each subsequent treatment line remains an important issue. In this retrospective study, we sought to identify pretreatment clinical parameters that could predict the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Eggers, Hendrik, Ivanyi, Philipp, Hornig, Mareike, Grünwald, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364333/
https://www.ncbi.nlm.nih.gov/pubmed/28405544
http://dx.doi.org/10.15586/jkcvhl.2017.59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364333/
https://www.ncbi.nlm.nih.gov/pubmed/28405544
http://dx.doi.org/10.15586/jkcvhl.2017.59

Ejemplares similares